Novavax President of R&D Gregory Glenn retiring March 31, signs consulting agreement through Dec 2024

NOVAVAX INC

Dr. Gregory Glenn steps down as President, R&D effective March 31, 2023.
Consulting agreement provides $25k/month for first 12 months, then $12.5k/month through Dec 31, 2024.
Equity awards continue to vest during consulting period; non-competition covenants begin post-retirement.
He will serve as Strategic Research & Development Advisor after retirement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gregory M. Glenn

President, Research and Development

NVAX · NOVAVAX INC

Effective: 2023-03-31
Filed: March 22, 2023, 7:59 PM ET

Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Gregory M. Glenn retired as President, Research and Development at NOVAVAX INC.

Action: retired
Role: President, Research and Development

Exact text from the filing

Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.

View on SEC.gov

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001000694-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.